ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2649

Trends in US Arthroplasty Rates 1991-2005: Patients with Inflammatory Arthritis Continue to Require Joint Replacement

Christina Mertelsmann-Voss1, Ting Jung Pan2, Stephen L. Lyman3, Mark P. Figgie4 and Lisa A. Mandl5, 1Pediatric Rheumatology, Hospital for Special Surgery, Cornell University, New York, NY, 2Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, 3Research, Hospital Special Surgery, New York, NY, 4Orthopedics, Hospital for Special Surgery, New York, NY, 5Rheumatology, Hospital for Special Surgery, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Arthroplasty, inflammatory arthritis, juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Orthopedics, Low Back Pain, and Rehabilitation

Session Type: Abstract Submissions (ACR)

Background/Purpose: Overall rates of total joint replacement surgeries (TJR) have increased dramatically over the past decades. By contrast, TJR rates among patients with rheumatoid arthritis (RA) are reported to be decreasing.  The magnitude of such change, and whether it applies to all types of inflammatory arthritis (IA), is not clear.  This study evaluates rates of TJR among patients with IA, [RA, juvenile idiopathic arthritis (JIA) and spondyloarthropathies (SpA)] and compares them to TJR patients with non-inflammatory conditions.

Methods:  Administrative hospital discharge databases from 10 states (AZ, CA, CO, FL, IA, MA, NJ, NY, WA, WI) and census data annual population estimates were used to calculate combined rates per 100,000 population of knee arthroplasty, total and partial hip arthroplasty, and total and partial shoulder arthroplasty from 1991 to 2005.    ICD-9-CM codes were used to identify specific diseases.

Results: There were 2,839,325 arthroplasties from 1991 to 2005, of which 76,665 (2.7%) were in IA patients. The proportion of TJR attributable to IA nearly halved during this period (3.9% in 1991 vs. 2.0% in 2005).  TJR rate for non-inflammatory conditions almost doubled from 124.5 in 1991 to 247.5 in 2005, while the rate in IA patients was fairly steady (range: 4.4-5.2). Stratifying by IA subtype, the TJR rate decreased slightly for RA (4.6 vs. 4.5, p-value<0.001) decreased by 40% for JIA (0.31 vs. 0.22, p-value<0.001), and increased by 40% for SpA (0.22 vs. 0.31 p-value<0.001). From 1991 to 2005, the mean age at TJR for IA patients across all disease subtypes increased: RA (63.4 yrs ±12.7 vs. 64.9 yrs ±12.8, p-value<0.001), JIA (30.9 yrs ±12.2 vs. 36.7 yrs ±14.9, p-value <0.001), and SpA (54.3 yrs ±16.1 vs. 60.4 yrs ±13.9, p-value <0.001). In contrast, the mean age of non-IA decreased (71.5±11.8 yrs. vs. 69.0±12.0 yrs p<0.001).  Among IA patients, neither age nor sex was statistically significantly related to TJR rates.

Conclusion: To our knowledge this is the largest cohort of TJR of patients with IA and the first study of TJR trends in patients with JIA and SpA. Surprisingly, TJR rates in RA showed minimal change despite the widespread introduction of methotrexate in the 1990s. JIA and SpA patients appear to be deferring TJR, with JIA patients requiring fewer procedures.  Why SpA TJR rates increased is unclear.  These data suggest there will be an ongoing need for orthopedists with expertise in operating on IA patients. Obtaining exposure during surgical training may be difficult, as the proportion of TJR cases due to IA is declining. Further research is needed to assess the effect of biologic medications, first introduced in 1998, on IA TJR rates.


Disclosure:

C. Mertelsmann-Voss,
None;

T. J. Pan,
None;

S. L. Lyman,
None;

M. P. Figgie,
None;

L. A. Mandl,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-in-us-arthroplasty-rates-1991-2005-patients-with-inflammatory-arthritis-continue-to-require-joint-replacement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology